MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Last months’ trends stayed pretty much on target with other recent months, with medtech titan Medtronic (NYSE:MDT) dominating the internet landscape, especially as new of the company’s disappointing renal denervation trial swept the market. Medtronic also posted major legal updates, including in a TAVI war with long-time rival Edwards Lifesciences (NYSE:EW) (which did not make it onto the list) and a CRM patent row with Boston Scientific (NYSE:BSX) (which landed in 4th place in the Trends chart).
Fellow healthcare giant Johnson & Johnson (NYSE:JNJ) took 2nd place, with its own Supreme Court level legal update, a few clinical trial reports and the $4.15 billion sale of its ortho-clinical diagnostics business. Covidien (NYSE:COV) took the 3rd seat, posting a 19% dip in quarterly profits, bailing on renal denervation development efforts and hunting for a new CFO to replace Charles Dockendorff.
Rounding out the list. St. Jude Medical (NYSE:STJ) came in 5th with plenty of news of its own, hitting new Wall Street heights, beating earnings expectations, shuffling its executive deck and landing wins with the FDA and at the patent office.
Medtronic
- Medtronic acquires drug/device maker TYRX for $160M
- Medtronic revisits atrial fibrillation ablation with VICTORY AF study
- Medtronic and St. Jude land new medtech patents
- Medtronic misses efficacy endpoint in Symplicity renal denervation trial
- Medtronic’s miss muddles the renal denervation landscape
- Medtronic CEO: Value-based healthcare is the only way to save medtech
- Medtronic, Stryker and Boston Scientific rank among best sales jobs in medtech
- Edwards Lifesciences wins a $393M round in TAVI patent war with Medtronic
- Renal denervation ‘highly unlikely’ for hypertension, says Medtronic study insider
- FDA OKs Medtronic’s CoreValve implant
- It’s not so Symple: the Rise (and Fall?) of Renal Denervation
- In defense of renal denervation: Managing expectations in the aftermath of Symplicity HTN-3
- Medtronic lands FDA win for full-body MRI with SureScan pacemakers
- Medtronic wins Supreme Court ruling in patent row with Boston Scientific
- Appeals court upholds Edwards Lifesciences win over Medtronic in heart valve spat
- Analysts warn of deeper impact of Medtronic’s renal denervation miss
- Medtronic moves to new Mid-East/Africa office
- Medtronic lands expanded FDA approval for Valiant Captivia
- Medtronic, J&J put more skin in PowerVision’s intraocular lens
- State appeals court reverses preempted Medtronic InFuse case
Johnson & Johnson
- J&J’s Synthes wins round in spat with ex-sales rep
- Johnson & Johnson’s ortho-clinical diagnostics goes to Carlyle for $4.15B
- Investors balk at J&J’s 2014 guidance despite Q4, 2013 growth
- J&J’s Codman Neuro recall upgraded to high risk Class I
- Covidien reports 19% profit dip and notches a win in J&J patent battle
- Cordis S.M.A.R.T. stent still looking good at 3 years
- Supreme Court denies stent pioneer Saffran in $600M patent case against J&J’s Cordis
- Baxter sues Johnson & Johnson over FloSeal patents
- Medtronic, J&J put more skin in PowerVision’s intraocular lens
- Big Data: Johnson & Johnson pledges transparency in clinical trial data
- Cordis releases 2-year data from Incraft stent trial
Covidien
- Covidien puts some skin in Irish medtech startup Fire1
- FDA issues Class I recall for Covidien ventilator
- Covidien CEO: Emerging markets a priority
- Covidien closes $235M divestiture of Confluent to Integra LifeSciences
- Covidien bails on renal denervation
- Covidien lands FDA 510(k) for 3-in-1 laparoscopic surgical device
- Covidien opens 1st India Center of Innovation
- Covidien reports 19% profit dip and notches a win in J&J patent battle
- Covidien hunts for new CFO
- Covidien lands Japanese approval for surgical staples
Boston Scientific
- Boston Scientific names new medical chief for interventional cardiology
- Ban to stand on Boston Scientific’s Guidezilla catheter
- Medtronic, Stryker and Boston Scientific rank among best sales jobs in medtech
- Boston Scientific stands fast on renal denervation
- Boston Scientific loses bid to dismiss pelvic mesh bellwether
- Medtronic wins Supreme Court ruling in patent row with Boston Scientific
- Boston Scientific donates $3.4M to Saint Luke’s cardiac research
- Supreme Court denies stent pioneer Saffran in $600M patent case against J&J’s Cordis
St. Jude Medical
- St. Jude Medical soars to new heights
- Medtronic and St. Jude land new medtech patents
- St. Jude Medical beats guidance with Q4 prelims
- St. Jude CEO: Medtronic’s renal denervation miss doesn’t dampen our spirits
- St. Jude Medical quietly lands FDA approval for Cool Flex cardiac ablation
- St. Jude Medical beats The Street with Q4, 2013 numbers
- Riata lawsuit claims stand against St. Jude Medical
- St. Jude touts 1st U.K. implant of ‘leadless’ Nanostim pacemaker
- St. Jude Medical shuffles the deck